广州医科大学附属第一医院
First Affiliated Hospital of Guangzhou Medical University
在本站收录的 61 种疾病中,这家医院列在其中 13 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
广州医科大学附属第一医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma6 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
- 肺癌Lung cancer186 篇牵头论文牵头 21 项开放试验
- 骨肉瘤Osteosarcoma0 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 淋巴瘤Lymphoma1 篇牵头论文
- 先天性心脏病Congenital heart disease2 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
- 大动脉炎Takayasu arteritis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis21 篇牵头论文
- 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis3 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、脊柱侧弯、肝包虫病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 24 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2024-03
- 发布
- 登记号
- NCT06301165
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心东莞、佛山、广州、武汉、深圳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文6
- Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.
- Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis.
- Dosimetric comparison and evaluation of different convergence modes in nasopharyngeal carcinoma using VMAT treatment deliveries.
- EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.
- Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
- Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
- A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
PubMed 以外找到的论文(未计入)9
- 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial
- A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.
- From immune architecture to clinical decision: Insights into the TLS‐based RNA model for metastatic risk in nasopharyngeal carcinoma
- MicroRNA-195-5p suppresses metastasis by targeting VEGFA in nasopharyngeal carcinoma
- Data from EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation
- Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.
- Additional file 2 of Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway
- M i R -182-5p I nduced by HIF-1α Promotes Tumorigenesis and Metastasis via Targeting ZFP36L1 in Nasopharyngeal Carcinoma
- The Oncogenic Role of HIF-1α/miR-182-5p/ZFP36L1 Signaling Pathway in Nasopharyngeal Carcinoma
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 11 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文3
- Translational selenium nanomedicine synergizes with nab-paclitaxel to enhance antitumor effects in esophageal squamous cell cancer via selenoprotein N-mediated ER stress.
- Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
- Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
PubMed 以外找到的论文(未计入)3
- Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
- Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
- Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 186 篇,占 0.8%。
广州有 17 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 53
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
- 分期
- II期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06926790
年龄 18 岁 至 80 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
- 分期
- 不分期
- 开始
- 2025-03
- 发布
- 登记号
- NCT07588737
年龄 18 岁 至 80 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06383728
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
- 分期
- III期
- 开始
- 2024-03
- 发布
- 登记号
- NCT06607796
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
- 分期
- 未注明
- 开始
- 2024-09
- 发布
- 登记号
- NCT06718972
年龄未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
- 分期
- II期
- 开始
- 2024-09
- 发布
- 登记号
- NCT06775275
年龄 18 岁 至 65 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
- 分期
- 未注明
- 开始
- 2024-01
- 发布
- 登记号
- NCT06843707
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
- 分期
- 不分期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06988579
年龄 40 岁 至 74 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Early Intervention Strategies for Lung Cancer
- 分期
- 不分期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06988943
年龄 40 岁 至 74 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
- 分期
- I/II期
- 开始
- 2023-07
- 发布
- 登记号
- NCT05777278
年龄 18 岁 至 未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
- 分期
- 不分期
- 开始
- 2023-09
- 发布
- 登记号
- NCT06286150
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
- 分期
- 未注明
- 开始
- 2019-06
- 发布
- 登记号
- NCT06778512
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募Non-risk Based Lang Cancer Screening With a One-off LDCT
- 分期
- 不分期
- 开始
- 2015-12
- 发布
- 登记号
- NCT04938804
年龄 40 岁 至 74 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- 分期
- II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07303881
年龄 18 岁 至 未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
- 分期
- I期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07318636
年龄 18 岁 至 未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
- 分期
- 不分期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07352176
年龄 18 岁 至 未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
- 分期
- 不分期
- 开始
- 2026-03
- 发布
- 登记号
- NCT07395375
年龄 18 岁 至 80 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Tubeless Strategy for Enhanced Recovery After Sublobar Resection
- 分期
- 不分期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07409129
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- 分期
- II期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07413952
年龄 18 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
- 分期
- II期
- 开始
- 2025-10
- 发布
- 登记号
- NCT07150416
年龄 18 岁 至 未注明(登记的条件)
牵头:广州医科大学附属第一医院广州
- 即将招募A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- 分期
- 不分期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06422637
年龄 40 岁 至 75 岁(登记的条件)
牵头:广州医科大学附属第一医院广州
- 正在招募A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- 分期
- I/II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07367529
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、中山、北京、南京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、扬州、杭州、武汉、西安、长沙
- 正在招募RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07416474
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛
- 正在招募Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
- 分期
- II期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07492342
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、广州、杭州
- 正在招募A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- 分期
- III期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07554339
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、台州、合肥、太原、广州、成都、杭州、桂林、武汉、济南、温州、石家庄、福州、重庆、长沙
- 正在招募A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- 分期
- II/III期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07739186
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州
- 正在招募A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- 分期
- III期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06875310
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙
- 正在招募Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06890598
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙
- 正在招募A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- 分期
- II/III期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07005102
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、南昌、广州、成都、武汉、福州
- 正在招募Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- 分期
- I/II期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07079475
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南京、天津、广州、成都、杭州、沈阳、济南、长沙
- 正在招募A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- 分期
- I/II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07111520
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛
- 正在招募Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- 分期
- III期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07154706
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、天津、广州、成都、杭州、武汉、济南、西安、郑州
- 正在招募A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07182682
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙
- 正在招募Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
- 分期
- 未注明
- 开始
- 2025-12
- 发布
- 登记号
- NCT07610616
年龄 18 岁 至 100 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州
- 正在招募PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
- 分期
- 未注明
- 开始
- 2025-10
- 发布
- 登记号
- NCT07775820
年龄 18 岁 至 未注明(登记的条件)
牵头:南方医科大学南方医院;另有 4 家列出的医院为研究中心南昌、广州、深圳、温州
- 正在招募A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- 分期
- III期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06312137
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南昌、台州、广州、成都、杭州、武汉、济南、福州、苏州、西安、郑州、长春、长沙
- 正在招募A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06345729
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙
- 正在招募Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- 分期
- III期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06422143
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、台州、哈尔滨、广州、成都、扬州、杭州、武汉、温州、福州、郑州、长春、长沙
- 正在招募A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- 分期
- III期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06452277
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、北京、南京、厦门、台州、哈尔滨、广州、成都、杭州、武汉、济南、福州、长春、长沙
- 正在招募A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- 分期
- I期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06461156
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州
- 正在招募Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- 分期
- II期
- 开始
- 2024-12
- 发布
- 登记号
- NCT06497530
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州
- 正在招募Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- 分期
- 未注明
- 开始
- 2024-06
- 发布
- 登记号
- NCT06518655
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、佛山、北京、广州、成都、武汉
- 正在招募Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
- 分期
- 未注明
- 开始
- 2024-06
- 发布
- 登记号
- NCT06528418
年龄 18 岁 至 100 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州
- 正在招募A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- 分期
- III期
- 开始
- 2024-10
- 发布
- 登记号
- NCT06561386
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、新乡、杭州、沈阳、济南、福州、重庆、长沙
- 正在招募A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- 分期
- III期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06564324
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、石家庄、苏州、西安、郑州、重庆、长沙
- 正在招募Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- 分期
- 不分期
- 开始
- 2024-09
- 发布
- 登记号
- NCT06572540
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、成都、杭州、郑州
- 正在招募A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06119581
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙
- 正在招募Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06170788
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙
- 正在招募A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2022-03
- 发布
- 登记号
- NCT04928846
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙
- 正在招募Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- 分期
- II期
- 开始
- 2022-09
- 发布
- 登记号
- NCT05168566
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙
- 正在招募Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- 分期
- II/III期
- 开始
- 2020-12
- 发布
- 登记号
- NCT04613596
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、杭州、武汉、沈阳、济南、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- 分期
- I/II期
- 开始
- 2019-07
- 发布
- 登记号
- NCT04270591
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、石家庄、郑州、长春、长沙
- 正在招募A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- 分期
- I期
- 开始
- 2018-04
- 发布
- 登记号
- NCT03460977
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心南京、广州、成都、温州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文186
- Symptom Clusters and Social Support in Patients With Lung Cancer Undergoing Anti-Programmed Death 1/Programmed Death Ligand 1 Immunotherapy: A Cross-sectional Analysis.
- Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.
- Commentary: Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer.
- Lactylation of HK2 facilitates cisplatin resistance in NSCLC by promoting cell migration, invasion, and glycolysis.
- High-dimensional single-cell analysis evaluating effects of different airway management strategies on perioperative immune cells in non-small cell lung cancer surgery.
- Objective Evaluation of Tubeless Thoracic Surgery in Early-Stage Lung Cancer Patients Using Multimodal Digital Device: A Prospective Study.
- Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer.
- Nebulized Inhalation of Engineered Extracellular Vesicles to Destruct Pre-metastatic Niche and Inhibit Postoperative Lung Metastasis in a Mouse Model.
- Accuracy of Contrast-enhanced Ultrasonography with Perfluorobutane for Diagnosing Subpleural Lung Lesions.
- Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer.
- Machine learning and discriminant analysis model for predicting benign and malignant pulmonary nodules.
- Cost-effectiveness of risk model-based lung cancer screening in smokers and nonsmokers in China.
- Composite dietary antioxidant index and lung cancer risk: insights from the UK biobank.
- Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021.
- Conservative management of postoperative incomplete lung torsion without reoperation: first case report with 2-year favorable outcomes.
- Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial.
- A novel optimized orthotopic mouse model for brain metastasis with sustained cerebral blood circulation and capability of multiple delivery.
- LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study.
- Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
- PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer.
- A-to-I edited SNHG3 promotes non-small cell lung cancer metastasis by promoting fatty acid oxidation and resisting ferroptosis.
- Prediction and immune infiltration analysis of lipid metabolism-related immune genes in the treatment of non-small cell lung cancer.
- Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
- Induction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.
- Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.
- Histomorphological and molecular spectrum of ciliated muconodular papillary tumors with implication for malignant potential: Insights from a literature review and series report.
- Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events.
- Mannose Inhibits NSCLC Growth and Inflammatory Microenvironment by Regulating Gut Microbiota and Targeting OGT/hnRNP R/JUN/IL-8 Axis.
- Integrating a Multimodal Digital Device for Continuous Perioperative Monitoring in Patients With Lung Cancer Undergoing Thoracic Surgery: Development and Usability Study.
- A Machine Learning Approach to Predicting Mortality Risk in Chemotherapy-Treated Lung Cancer: Machine Learning Model Development and Validation.
- Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.
- NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC.
- Advancements in diagnosis and treatment of lung adenocarcinoma patients under ECMO support: a case series and comprehensive literature review.
- Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
- Comparative Study of Sonazoid and SonoVue Contrast-Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions.
- circPRMT10 regulated by QKI hypermethylation attenuates lung tumorigenesis induced by tobacco carcinogen NNK.
- Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.
- The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
- Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.
- Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.
- Causal association and potential mediator between lung cancer and tuberculosis: A Mendelian randomization study.
- RNF6 Inhibits Lung Adenocarcinoma Cell Proliferation by Promoting Cyclin D2 Degradation.
- Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients.
- Comparison of three specimen collection techniques in tissue coagulum clot-based cell block preparation of endobronchial ultrasound-guided transbronchial needle aspiration.
- The diagnostic performance and optimal strategy of cone beam CT-assisted bronchoscopy for peripheral pulmonary lesions: A systematic review and meta-analysis.
- CT-based Radiologic Ternary Classification Model in Predicting Pathologic Invasiveness of Pulmonary Nonsolid Nodules.
- How I Do It: Management of Pleural-attached Pulmonary Nodules in Low-Dose CT Screening for Lung Cancer.
- A rhodamine-coordinated iridium complex to overcome cisplatin-resistant cancer via regulating mitochondrial function triggered apoptosis and ferroptosis.
- A LncRNA panel within EpCAM-specific exosomes for noninvasive early diagnosing non-small cell lung cancer.
- One-step diagnosis of infection and lung cancer using metagenomic sequencing.
- Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII).
- Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.
- Night shift work and lung cancer risk: a prospective cohort study with mediator analysis from the UK Biobank.
- Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer.
- Circular RNA circ_0004470 accelerates the occurrence of lung cancer by promoting DNA damage and cell cycle arrest.
- Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.
- Efficacy and safety of novel airway balloon cryoablation system for malignant central airway obstruction: a prospective, multicentre, randomised, non-inferiority study.
- Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience.
- Intrapulmonary Epstein-Barr Virus-Associated Smooth Muscle Tumor after Bilateral Lung Transplantation: A Case Report.
- Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I-III NSCLC.
- Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.
- First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma.
- Sub-lobar resection versus lobectomy for challenging intraoperative frozen sections in lung adenocarcinoma within 3 cm.
- Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.
- A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.
- Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.
- Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis.
- Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report.
- Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC.
- [18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study.
- Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions.
- LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
- A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules.
- EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.
- Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.
- Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.
- Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis.
- Circular RNA circNIPBL regulates TP53-H179R mutations in NNK-induced bronchial epithelial carcinogenesis.
- Development of a nomogram for predicting survival in clinical T1N0M1 lung adenocarcinoma: a population-based study.
- [64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window.
- The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study.
- Lower respiratory tract microbiome and lung cancer risk prediction in patients with diffuse lung parenchymal lesions.
- Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.
- Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.
- Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study.
- High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.
- Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.
- Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy.
- Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis.
- Exploring the molecular and immune-landscape of lung cancer associated with cystic airspaces.
- Supervised training models with or without manual lesion delineation outperform clinicians in distinguishing pulmonary cryptococcosis from lung adenocarcinoma on chest CT.
- Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.
- Solitary pulmonary capillary hemangioma - An underrecognized rare tumor. Report of 32 new cases with literature review.
- An original aneuploidy-related gene model for predicting lung adenocarcinoma survival and guiding therapy.
- The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
- Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
- Solitary Renal Metastases From Stage IA Primary Lung Adenocarcinoma With Co-Alteration of EGFR, RB1, and MAP3K1: A Case Report.
- A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model.
- Circ0087385 promotes DNA damage in benzo(a)pyrene-induced lung cancer development by upregulating CYP1A1.
- Neoadjuvant immunochemotherapy-a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma.
- The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.
- Construction and Validation of a Prognostic Model Based on Novel Senescence-Related Genes in Non-Small Cell Lung Cancer Patients with Drug Sensitivity and Tumor Microenvironment.
- Behind the Indolent Facade: Uncovering the Molecular Features and Malignancy Potential in Lung Minimally Invasive Adenocarcinoma by Single-Cell Transcriptomics.
- Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma.
- Diagnostic performance of diffusion-weighted imaging versus 18F-FDG PET/CT in differentiating pulmonary lesions: an updated meta-analysis of comparative studies.
- Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
- A surgical Decision-making scoring model for spontaneous ventilation- and mechanical ventilation-video-assisted thoracoscopic surgery in non-small-cell lung cancer patients.
- A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
- USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl.
- Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil.
- Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.
- A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.
- Sublobar resection reduces the risk of postoperative cognitive dysfunction compared with lobectomy.
- Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment.
- Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report.
- Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.
- A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
- Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
- Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
- The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis.
- Risk mapping of lung cancer: a comprehensive appraisal of published meta-analyses incorporating Mendelian randomization studies.
- Theranostic applications of selenium nanomedicines against lung cancer.
- The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
- Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test.
- Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
- Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
- Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report.
- Accurate and Convenient Lung Cancer Diagnosis through Detection of Extracellular Vesicle Membrane Proteins via Förster Resonance Energy Transfer.
- 5G-Based Remote Virtual Bronchoscopic Navigation-Guided Transbronchial Lung Biopsy for Diagnosis of Lung Cancer: Description of 2 Cases.
- Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study.
- The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.
- Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer.
- Current status of diagnosis and treatment of advanced non-small cell lung cancer in China during the COVID-19 pandemic.
- Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.
- Nonintubated Robotic-assisted Thoracic Surgery for Tracheal/Airway Resection and Reconstruction: Technique Description and Preliminary Results.
- Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
- Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.
- Characterization of the fatty acid metabolism-related genes in lung adenocarcinoma to guide clinical therapy.
- GMFG (glia maturation factor gamma) inhibits lung cancer growth by activating p53 signaling pathway.
- Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion.
- Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.
- Video-assisted thoracic surgery for ambiguous lung or mediastinal masses in response assessments for hematological malignancies.
- The CT and PET/CT findings in primary pulmonary lymphoepithelioma-like carcinoma with pathological correlation: a study of 215 cases.
- PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
- DNMT3A-mediated high expression of circ_0057504 promotes benzo[a]pyrene-induced DNA damage via the NONO-SFPQ complex in human bronchial epithelial cells.
- Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.
- Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
- Family Socioeconomic Position and Lung Cancer Risk: A Meta-Analysis and a Mendelian Randomization Study.
- PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.
- Spontaneous Ventilation Video-Assisted Thoracoscopic Surgery for Geriatric Patients With Non-Small-Cell Lung Cancer.
- Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Predicting and Monitoring the Response of Anti-Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma.
- Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.
- Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study.
- Hierarchical clock-scale hand-drawn mapping as a simple method for bronchoscopic navigation in peripheral pulmonary nodule.
- Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer.
- Involvement of m6A regulatory factor IGF2BP1 in malignant transformation of human bronchial epithelial Beas-2B cells induced by tobacco carcinogen NNK.
- Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
- Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.
- Values of Apparent Diffusion Coefficient and Lesion-to-Spinal Cord Signal Intensity in Diagnosing Solitary Pulmonary Lesions: Turbo Spin-Echo versus Echo-Planar Imaging Diffusion-Weighted Imaging.
- CUBIC-plus: An optimized method for rapid tissue clearing and decolorization.
- Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
- Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.
- Notch1/TAZ axis promotes aerobic glycolysis and immune escape in lung cancer.
- Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
- Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
- Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.
- Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.
- Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
- Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.
- Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
- Circ0001320 inhibits lung cancer cell growth and invasion by regulating TNFAIP1 and TPM1 expression through sponging miR-558.
- Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.
- Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.
- DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
- The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
- Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
- Lung cancer risk in patients with multiple sclerosis: a Mendelian randomization analysis.
- Pulmonary artery intimal sarcoma - A primeval or rediscovered tumor? A report of 14 new cases with literature review.
- Feasibility and Safety of Radiofrequency Ablation Guided by Bronchoscopic Transparenchymal Nodule Access in Canines.
- Rheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study.
- The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer.
- Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study.
- Family History Associates With Micropapillary Pattern in Lung Adenocarcinoma ≤1.0 cm.
- Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
- Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
- A genome-wide screen for differentially methylated long noncoding RNAs identified that lncAC007255.8 is regulated by promoter DNA methylation in Beas-2B cells malignantly transformed by NNK.
中文论文(未计入)18
- [Annual review of interventional pulmonology 2024].
- [Evaluation of 18F-fibroblast activation protein inhibitor-42 PET/CT in lymphangioleiomyomatosis and its correlation with vascular endothelial growth factor-D].
- [An analysis of clinical and genetic feature in pulmonary artery sarcoma].
- [Annual therapeutic advances in advanced non-small cell lung cancer in 2024].
- [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review].
- [Molecular Subtype of Small Cell Lung Cancer: Challenge for Transforming into Clinical Practice].
- [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 in Mouse Lung Cancer].
- [Results of Lung Cancer Screening with Low-dose Computed Tomography and Exploration of Risk Factors in Guangzhou].
- [Cytology Smears of Rapid On-site Evaluation as Supplemental Material for Molecular Testing of Non-small Cell Lung Cancer].
- [Brief analysis of diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease].
- [Analysis of the efficacy and safety of dual immunotherapy in patients with driver gene and programmed death ligand-1 double negative advanced non-small cell lung cancer].
- [Analysis of Clinicopathological Features on Spread Through Air Spaces of Lung Adenocarcinoma].
- [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy].
- [Research Progress on Spread Through Air Spaces of Lung Cancer].
- [Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: the Progress and Clinical Application].
- [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
- [Analysis of the Relationship Between the Quality of Small Biopsy Specimens of Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene].
- [Predictive value of combined detection tumor markers in the diagnosis of lung cancer].
它在 ClinicalTrials.gov 上的全部试验(任何状态)152
- Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
- NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
- Tubeless Strategy for Enhanced Recovery After Sublobar Resection
- Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
- Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
- Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
- The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
- Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
- Early Intervention Strategies for Lung Cancer
- A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
- Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
- A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
- Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
- LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
- Non-risk Based Lang Cancer Screening With a One-off LDCT
- Real-Time Non-Invasive Localization for Multiple Lung Nodules
- Tubeless VATS for Lung Cancer Surgery
- Robotic-Assisted Navigation for Lung Nodule Localization: A Non-Inferiority Study
- A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy
- Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
- A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
- A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
- A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
- The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.
- A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
- A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes
- A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
- Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
- Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
- A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer
- Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung
- Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With LAP Protector
- Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer
- Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors
- Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer
- Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer
- Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
- Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer
- Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
- A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
- Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
- ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery
- Safety and Feasibility of Remote Robotic Bronchoscopy for Peripheral Lung Cancer: A Multicenter, Proof-of-concept Study
- A Single-arm Exploratory Study of Neoadjuvant Therapy
- Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
- The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
- A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
- A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
- HTA of NIVATS Based on RWE
- A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor
- Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
- A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
- Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- Crizotinib Continuation Clinical Study
- Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
- A Study of Smoking Cessation Patterns in Participants Undergoing Lung Surgery
- A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers
- A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
- A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
- Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
- A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC
- Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
- Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
- Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
- Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
- NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
- A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2
- Plasmodium Immunotherapy for Lung Cancer
- Afatinib in NSCLC With HER2 Mutation
- Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
- Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
- Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
- A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
- A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
- Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
- A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
- Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
癌症
骨肉瘤
Osteosarcoma2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 30 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
早期论文(2016–2020 年)3
- Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.
- Quercetin Inhibits Cell Migration and Invasion in Human Osteosarcoma Cells.
- Overexpression of long non-coding RNA MFI2 promotes cell proliferation and suppresses apoptosis in human osteosarcoma.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 22 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.03%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 16 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- 分期
- I期
- 开始
- 2018-04
- 发布
- 登记号
- NCT03460977
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心南京、广州、成都、温州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
- A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
- Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
其他疾病
先天性心脏病
Congenital heart disease2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 12 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 6 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 21 篇,占 2.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 20 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- 分期
- II期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07121413
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文21
- Machine learning-based integration identifies plasma cells-related gene signature ST6GAL1 in idiopathic pulmonary fibrosis.
- Impaired ciliogenesis in small airway epithelial cells involves in the development of idiopathic pulmonary fibrosis.
- Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study.
- Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.
- Multiomic analysis of monocyte-derived alveolar macrophages in idiopathic pulmonary fibrosis.
- Characterizing the lavage and serum cytokine profiles of interstitial pneumonia with autoimmune features and their implications for progressive fibrosis.
- Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway.
- Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: a mendelian randomization study.
- Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration.
- Repairing Mechanisms for Distal Airway Injuries and Related Targeted Therapeutics for Chronic Lung Diseases.
- LncRNA GAS5 suppresses TGF-β1-induced transformation of pulmonary pericytes into myofibroblasts by recruiting KDM5B and promoting H3K4me2/3 demethylation of the PDGFRα/β promoter.
- Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis.
- Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.
- Outcomes after lung transplantation among Chinese patients with connective tissue disease-associated interstitial lung disease and pulmonary hypertension: a retrospective cohort study.
- Identification and validation of autophagy-related gene expression for predicting prognosis in patients with idiopathic pulmonary fibrosis.
- Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.
- Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway.
- Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts.
- Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.
- Deleterious Role of Th9 Cells in Pulmonary Fibrosis.
- Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.
早期论文(2016–2020 年)5
- Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
- Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.
- Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
- The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study.
- Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肺淋巴管平滑肌瘤病
Lymphangioleiomyomatosis2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 3 篇,占 6.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。
这些数字背后的记录
牵头的论文3
- Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.
- Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis.
- Safety and efficacy of cryobiopsy for the diagnosis of lymphangioleiomyomatosis compared with forceps biopsy and surgical lung biopsy.
中文论文(未计入)2
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 9 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 6 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
联系这家医院
出示给工作人员或司机的院名卡
广州医科大学附属第一医院
First Affiliated Hospital of Guangzhou Medical University
广州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药